Linked Data API

Show Search Form

Search Results

386886
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Bone Marrow Disorders more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL995 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thisremove minimum value filter
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL996 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.197Zmore like thismore than 2015-07-14T15:34:29.197Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386887
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL996 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thisremove minimum value filter
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.297Zmore like thismore than 2015-07-14T15:34:29.297Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386888
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL997 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thisremove minimum value filter
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL996 more like this
star this property question first answered
less than 2015-07-14T15:34:29.553Zmore like thismore than 2015-07-14T15:34:29.553Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386489
star this property registered interest false more like this
star this property date less than 2015-06-30more like thismore than 2015-06-30
star this property answering body
Department for Work and Pensions more like this
star this property answering dept id 29 more like this
unstar this property answering dept short name Work and Pensions more like this
star this property answering dept sort name Work and Pensions more like this
star this property hansard heading Employment: Autism more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what efforts they are making to raise awareness of employing people with autism. more like this
star this property tabling member printed
Baroness Uddin more like this
star this property uin HL984 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thisremove minimum value filter
unstar this property answer text <p>The Government is acting to raise awareness regarding employment of people with autism and to support people on the autism spectrum to take up employment. For example,</p><p> </p><p>The Government’s Disability Confident campaign works with employers at a national and local level to help them to understand the benefits of employing disabled people, and promote good practice in recruitment and employment of disabled people, including people with autism.</p><p> </p><p>DWP has worked in close partnership with the Hidden Impairment National Group (HING), a national network of disabled people, medical professionals/ academics and disability specific organisations to produce an ‘Uncovering Hidden Impairments’ toolkit. This resource supports organisations in both the private and public sectors to confidently recruit and retain talented individuals with hidden impairment conditions.</p><p> </p><p>The Department for Education is funding <em>Ambitious about Autism </em>(2015-16) to explore innovative ways of supporting young people with Autism to make the transition from school to further education, and the <em>Autism Education Trust</em> (2015-16) to promote the availability of training on Autism to schools, early years and further education staff, and to revise national standards for Autism provision and a competency framework for those who work with children with Autism.</p><p> </p><p>Government has supported the development by NIACE of an employer toolkit that includes information to help employers to understand the benefits of employing apprentices with disabilities, and to access support.</p><p> </p><p>We are currently working with Autism charities to build an autism network across DWP Jobcentre Plus Offices to ensure we can provide the best possible service to those with autism.</p><p> </p><p>We have worked with Community Service Volunteers to introduce the Job-Shadowing Work Placement Initiative for young disabled people. The first tranche was very successful with 65% of young people having autistic spectrum conditions</p><p> </p><p>The Government’s Autism Strategy, and the updated Statutory Guidance published in March 2015, sets out in detail how Government will support the autism agenda nationally.</p>
star this property answering member printed Baroness Altmann more like this
star this property grouped question UIN HL985 more like this
star this property question first answered
less than 2015-07-14T12:34:45.44Zmore like thismore than 2015-07-14T12:34:45.44Z
star this property answering member
4533
star this property label Biography information for Baroness Altmann more like this
star this property tabling member
1827
unstar this property label Biography information for Baroness Uddin more like this
386490
star this property registered interest false more like this
star this property date less than 2015-06-30more like thismore than 2015-06-30
star this property answering body
Department for Work and Pensions more like this
star this property answering dept id 29 more like this
unstar this property answering dept short name Work and Pensions more like this
star this property answering dept sort name Work and Pensions more like this
star this property hansard heading Employment: Autism more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what steps they will take to ensure that organisations in the private sector employ people with autism. more like this
star this property tabling member printed
Baroness Uddin more like this
star this property uin HL985 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thisremove minimum value filter
unstar this property answer text <p>The Government is acting to raise awareness regarding employment of people with autism and to support people on the autism spectrum to take up employment. For example,</p><p> </p><p>The Government’s Disability Confident campaign works with employers at a national and local level to help them to understand the benefits of employing disabled people, and promote good practice in recruitment and employment of disabled people, including people with autism.</p><p> </p><p>DWP has worked in close partnership with the Hidden Impairment National Group (HING), a national network of disabled people, medical professionals/ academics and disability specific organisations to produce an ‘Uncovering Hidden Impairments’ toolkit. This resource supports organisations in both the private and public sectors to confidently recruit and retain talented individuals with hidden impairment conditions.</p><p> </p><p>The Department for Education is funding <em>Ambitious about Autism </em>(2015-16) to explore innovative ways of supporting young people with Autism to make the transition from school to further education, and the <em>Autism Education Trust</em> (2015-16) to promote the availability of training on Autism to schools, early years and further education staff, and to revise national standards for Autism provision and a competency framework for those who work with children with Autism.</p><p> </p><p>Government has supported the development by NIACE of an employer toolkit that includes information to help employers to understand the benefits of employing apprentices with disabilities, and to access support.</p><p> </p><p>We are currently working with Autism charities to build an autism network across DWP Jobcentre Plus Offices to ensure we can provide the best possible service to those with autism.</p><p> </p><p>We have worked with Community Service Volunteers to introduce the Job-Shadowing Work Placement Initiative for young disabled people. The first tranche was very successful with 65% of young people having autistic spectrum conditions</p><p> </p><p>The Government’s Autism Strategy, and the updated Statutory Guidance published in March 2015, sets out in detail how Government will support the autism agenda nationally.</p>
star this property answering member printed Baroness Altmann more like this
star this property grouped question UIN HL984 more like this
star this property question first answered
less than 2015-07-14T12:34:45.583Zmore like thismore than 2015-07-14T12:34:45.583Z
star this property answering member
4533
star this property label Biography information for Baroness Altmann more like this
star this property tabling member
1827
unstar this property label Biography information for Baroness Uddin more like this
384475
star this property registered interest false more like this
star this property date less than 2015-06-22more like thismore than 2015-06-22
star this property answering body
Home Office more like this
star this property answering dept id 1 more like this
unstar this property answering dept short name Home Office more like this
star this property answering dept sort name Home Office more like this
star this property hansard heading Deportation: China more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what assessment they have made of the petition initiated by the children of Chinese sailors deported from Liverpool after World War Two. more like this
star this property tabling member printed
Lord Alton of Liverpool more like this
star this property uin HL686 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-20more like thismore than 2015-07-20
unstar this property answer text <p>No information is held by the Home Office. Surviving files were transferred to the National Archives in 1980; these are open to the public in class HO 213. The Noble Lord is invited to forward to the Home Office any additional information for officials to consider.</p> more like this
star this property answering member printed Lord Bates more like this
star this property grouped question UIN
HL687 more like this
HL688 more like this
star this property question first answered
less than 2015-07-20T16:30:35.227Zmore like thismore than 2015-07-20T16:30:35.227Z
star this property answering member
1091
star this property label Biography information for Lord Bates more like this
star this property tabling member
738
unstar this property label Biography information for Lord Alton of Liverpool more like this
384476
star this property registered interest false more like this
star this property date less than 2015-06-22more like thismore than 2015-06-22
star this property answering body
Home Office more like this
star this property answering dept id 1 more like this
unstar this property answering dept short name Home Office more like this
star this property answering dept sort name Home Office more like this
star this property hansard heading Deportation: China more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what information they hold about the circumstances in which Chinese fathers who had been recruited to serve in British Merchant Navy Atlantic convoys were, in 1946, compulsorily repatriated, leaving their children; and whether they will place this information in the Library of the House. more like this
star this property tabling member printed
Lord Alton of Liverpool more like this
star this property uin HL687 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-20more like thismore than 2015-07-20
unstar this property answer text <p>No information is held by the Home Office. Surviving files were transferred to the National Archives in 1980; these are open to the public in class HO 213. The Noble Lord is invited to forward to the Home Office any additional information for officials to consider.</p> more like this
star this property answering member printed Lord Bates more like this
star this property grouped question UIN
HL686 more like this
HL688 more like this
star this property question first answered
less than 2015-07-20T16:30:35.32Zmore like thismore than 2015-07-20T16:30:35.32Z
star this property answering member
1091
star this property label Biography information for Lord Bates more like this
star this property tabling member
738
unstar this property label Biography information for Lord Alton of Liverpool more like this
384477
star this property registered interest false more like this
star this property date less than 2015-06-22more like thismore than 2015-06-22
star this property answering body
Home Office more like this
star this property answering dept id 1 more like this
unstar this property answering dept short name Home Office more like this
star this property answering dept sort name Home Office more like this
star this property hansard heading Deportation: China more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what assessment they have made of the false information given by government officials to the children of Chinese men compulsorily repatriated in 1946 that their fathers had been killed at sea or abandoned them, and the consequences for the children and their mothers; and whether the Home Secretary will agree to meet some of the surviving children. more like this
star this property tabling member printed
Lord Alton of Liverpool more like this
star this property uin HL688 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-20more like thismore than 2015-07-20
unstar this property answer text <p>No information is held by the Home Office. Surviving files were transferred to the National Archives in 1980; these are open to the public in class HO 213. The Noble Lord is invited to forward to the Home Office any additional information for officials to consider.</p> more like this
star this property answering member printed Lord Bates more like this
star this property grouped question UIN
HL686 more like this
HL687 more like this
star this property question first answered
less than 2015-07-20T16:30:35.127Zmore like thismore than 2015-07-20T16:30:35.127Z
star this property answering member
1091
star this property label Biography information for Lord Bates more like this
star this property tabling member
738
unstar this property label Biography information for Lord Alton of Liverpool more like this
386926
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Vitamin B12 more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what assessment they have made of the frequency at which patients with pernicious anaemia require vitamin B12 replacement therapy by injection; whether they have any evidence that patients are purchasing additional supplies from unregulated sources; and whether they will review current guidance. more like this
star this property tabling member printed
The Countess of Mar more like this
star this property uin HL1035 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thisremove minimum value filter
unstar this property answer text <p>The diagnosis and treatment of pernicious anaemia, the result of a vitamin B12 (cobalamin) deficiency, is well established and reported in the British Committee for Standards in Haematology (BCSH) guidance document, <em>Guidelines for the diagnosis and treatment of Cobalamin and Folate disorders</em>, which was updated in May 2014. A copy of the BCSH guidance document is attached.</p><p> </p><p>The BCSH operates independently of the Department and NHS England and produces evidence based guidelines for both clinical and laboratory haematologists on the diagnosis and treatment of haematological disease, drawing on the advice of expert consultants and clinical scientists practicing in the United Kingdom. It would be for the BCSH, not the Department, to consider whether any adjustments to current best practice, in the diagnosis and treatment of patients with pernicious anaemia were needed, including whether any new or additional tests were appropriate.</p><p> </p><p> </p><p> </p><p>The BCSH guidance sets out that cobalamin status is the recommended first line diagnostic test. The Department has no data relating to false positive results in relation to the test. The guidance also states that clinical picture is the most important factor in assessing the significance of the test results.</p><p> </p><p> </p><p> </p><p>When anaemia is diagnosed, most patients respond well to treatment through quarterly intramuscular injection of vitamin B12. Whilst some patients with pernicious anaemia might prefer to have more frequent injections, or for other forms of vitamin B12 to be self-administered, these are matters for individual patients to discuss with their general practitioners.</p><p> </p><p> </p><p> </p><p>Although the Medicines Healthcare products Regulatory Agency is currently reviewing claims made by some clinics that are administering vitamins and minerals intravenously for nutritional therapy purposes, the agency has not encountered any clinics making claims to treat pernicious anaemia. In addition, the Department does not have any information regarding patients purchasing additional supplies of B12 from unregulated sources.</p><p> </p><p> </p><p> </p><p>Regarding the mandatory fortification of flour with folic acid, the Scientific Advisory Committee on Nutrition recommended a number of measures to ensure monitoring and surveillance of the impact of fortification of flour, should it be implemented. This included appropriate systems to monitor any potential adverse effects, including cancer and a review of the evidence on benefits and postulated risks after five years. The National Diet and Nutrition Survey monitors folate intakes and the most recent data, which was published earlier this year, will be carefully considered alongside other information sources before any decision is made on mandatory fortification.</p><p> </p><p> </p><p> </p><p>The Department has made no assessment of the social and economic costs of misdiagnosis or late diagnosis of pernicious anaemia and other vitamin B12 deficiencies.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL1032 more like this
HL1033 more like this
HL1034 more like this
HL1036 more like this
HL1042 more like this
star this property question first answered
less than 2015-07-14T15:00:42.073Zmore like thismore than 2015-07-14T15:00:42.073Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name colbalamin and folate disorders.pdf more like this
star this property title BSCH Guidance more like this
star this property tabling member
1861
unstar this property label Biography information for The Countess of Mar more like this
386927
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Vitamin B12 more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether they have assessed the social and economic costs of misdiagnosis or late diagnosis of pernicious anaemia and other vitamin B12 deficiencies; and, if so, what they consider them to be. more like this
star this property tabling member printed
The Countess of Mar more like this
star this property uin HL1036 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thisremove minimum value filter
unstar this property answer text <p>The diagnosis and treatment of pernicious anaemia, the result of a vitamin B12 (cobalamin) deficiency, is well established and reported in the British Committee for Standards in Haematology (BCSH) guidance document, <em>Guidelines for the diagnosis and treatment of Cobalamin and Folate disorders</em>, which was updated in May 2014. A copy of the BCSH guidance document is attached.</p><p> </p><p>The BCSH operates independently of the Department and NHS England and produces evidence based guidelines for both clinical and laboratory haematologists on the diagnosis and treatment of haematological disease, drawing on the advice of expert consultants and clinical scientists practicing in the United Kingdom. It would be for the BCSH, not the Department, to consider whether any adjustments to current best practice, in the diagnosis and treatment of patients with pernicious anaemia were needed, including whether any new or additional tests were appropriate.</p><p> </p><p> </p><p> </p><p>The BCSH guidance sets out that cobalamin status is the recommended first line diagnostic test. The Department has no data relating to false positive results in relation to the test. The guidance also states that clinical picture is the most important factor in assessing the significance of the test results.</p><p> </p><p> </p><p> </p><p>When anaemia is diagnosed, most patients respond well to treatment through quarterly intramuscular injection of vitamin B12. Whilst some patients with pernicious anaemia might prefer to have more frequent injections, or for other forms of vitamin B12 to be self-administered, these are matters for individual patients to discuss with their general practitioners.</p><p> </p><p> </p><p> </p><p>Although the Medicines Healthcare products Regulatory Agency is currently reviewing claims made by some clinics that are administering vitamins and minerals intravenously for nutritional therapy purposes, the agency has not encountered any clinics making claims to treat pernicious anaemia. In addition, the Department does not have any information regarding patients purchasing additional supplies of B12 from unregulated sources.</p><p> </p><p> </p><p> </p><p>Regarding the mandatory fortification of flour with folic acid, the Scientific Advisory Committee on Nutrition recommended a number of measures to ensure monitoring and surveillance of the impact of fortification of flour, should it be implemented. This included appropriate systems to monitor any potential adverse effects, including cancer and a review of the evidence on benefits and postulated risks after five years. The National Diet and Nutrition Survey monitors folate intakes and the most recent data, which was published earlier this year, will be carefully considered alongside other information sources before any decision is made on mandatory fortification.</p><p> </p><p> </p><p> </p><p>The Department has made no assessment of the social and economic costs of misdiagnosis or late diagnosis of pernicious anaemia and other vitamin B12 deficiencies.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL1032 more like this
HL1033 more like this
HL1034 more like this
HL1035 more like this
HL1042 more like this
star this property question first answered
less than 2015-07-14T15:00:42.183Zmore like thismore than 2015-07-14T15:00:42.183Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name colbalamin and folate disorders.pdf more like this
star this property title BSCH Guidance more like this
star this property tabling member
1861
unstar this property label Biography information for The Countess of Mar more like this